Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  FibroGen Inc    FGEN

FIBROGEN INC (FGEN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 194 M
EBIT 2018 -99,2 M
Net income 2018 -128 M
Finance 2018 672 M
Yield 2018 -
Sales 2019 264 M
EBIT 2019 -80,1 M
Net income 2019 -91,2 M
Finance 2019 668 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 20,3x
EV / Sales2019 14,9x
Capitalization 4 607 M
More Financials
Company
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs.It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas.The company was founded by Thomas B. Neff on September 29, 1993 and is... 
More about the company
Surperformance© ratings of FibroGen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FIBROGEN INC
10/16FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming Amer..
GL
10/03ASTELLAS PHARMA : Submits New Drug Application in Japan of Roxadustat for The Tr..
AQ
10/01FIBROGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/01FIBROGEN : Astellas Submits New Drug Application in Japan of Roxadustat for The ..
AQ
09/21Roxadustat meets in Phase III for CKD patients with anemia not on dialysis
AQ
09/20FIBROGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/13FIBROGEN : Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for..
AQ
09/12FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab fo..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
10/19FDA Approves Asthma Indication for Regeneron and Sanofi's Dupixent
DJ
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/18Leerink Swann Analysts Give FibroGen $FGEN a $84.00 Price Target  
10/17Q3 2018 Earnings Forecast for FibroGen Inc $FGEN Issued By Leerink Swann  
10/17Leerink Swann Lowers FibroGen Q3 2018 Earnings Estimates to ($0.30) EPS (Prev.. 
10/17FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming Amer.. 
10/15Want the latest analyst ratings on $AMBR $AHH $TSC $FGEN $ADMS? Get Them Deli.. 
More tweets
Qtime:61
News from SeekingAlpha
10/19Key events next week - healthcare 
10/02NASH players under pressure following Liver Meeting abstract drop 
09/27HighTide's HTD1801 Fast Track'd for PSC 
09/24BIOTECH STOCKS : Niche Operators Scientifically, Competing Directly As Investmen.. 
09/15YOUR DAILY PHARMA SCOOP : FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myer.. 
Chart FIBROGEN INC
Duration : Period :
FibroGen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIBROGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 71,8 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Thomas Byron Neff Chairman & Chief Executive Officer
Pat Cotroneo Chief Financial Officer & Vice President-Finance
Kin Hung Yu Chief Medical Officer
Jorma Tapio Routti Independent Director
Kalevi Kurkijärvi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FIBROGEN INC4.79%4 607
CELLTRION, INC.--.--%28 844
IQVIA HOLDINGS INC26.93%26 016
LONZA GROUP18.00%24 556
INCYTE CORPORATION-34.51%13 698
SEATTLE GENETICS, INC.36.58%11 706